StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

Prostacyclin

HCID 5282411
Neue Reaktion
Drucken

Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen

GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
35121-78-9
Standard-SMILES
CCCCC[C@H](O)/C=C/[C@@H]1[C@H]2C/C(=C/CCCC(=O)O)O[C@H]2C[C@H]1O
InChIKey
KAQKFAOMNZTLHT-OZUDYXHBSA-N
Summenformel
C20H32O5
Durchschnittliche Molmasse
352,5 g/mol
Monoisotopische Masse
352,22497412

Überblick

Prostaglandin I2 is a prostaglandins I. It has a role as a mouse metabolite. It is a conjugate acid of a prostaglandin I2(1-).

Namen und Bezeichner

Bevorzugter Name
Prostacyclin
IUPAC
(5Z)-5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid
Englischer Name
Epoprostenol
Summenformel
C20H32O5
Molmasse
352.47

Namen und Synonyme

epoprostenolprostacyclinprostaglandin I235121-78-9VasocyclinProstaglandin XPGI2EpoprostenolumACT-385781ADCR9Z582X0U-53217(5Z)-5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid
Weitere Namen anzeigen
PGXPGl2U 53217U-53217ACyclo-ProstinProstaglandinI(+)-AlismoxideProstaglandin l2
(5Z,9alpha,11alpha,13E,15S)-6,9-epoxy-11,15-dihydroxyprosta-5,13-dien-1-oic acidU-53,217DTXSID5022988CHEBI:155526,9S-epoxy-11R,15S-dihydoxy-5Z,13E-prostadienoic acidEpoprostanol(5Z,13E)-(15S)-6,9alpha-Epoxy-11alpha,15-dihydroxyprosta-5,13-dienoateProsta-5,13-dien-1-oic acid, 6,9-epoxy-11,15-dihydroxy-, (5Z,9alpha,11alpha,13E,15S)-

Datenbank-Bezeichner

CAS
35121-78-9
PubChem CID
5282411
DTXSID
DTXSID5022988
ChEMBL
CHEMBL1139
ChEBI
CHEBI:15552
UNII
DCR9Z582X0
Nikkaji
J17.550A

Eigenschaften

Berechnete StruktureigenschaftenWird ergänzt

XLogP
2,9
Polarare Oberfläche (TPSA)
87 Ų
H-Brücken-Donoren
3
H-Brücken-Akzeptoren
5
Frei drehbare Bindungen
10
Schwere Atome
25
Formalladung
0
Komplexität
484

Experimentelle und physikochemische Eigenschaften

DrugsPharmaceuticals -> Listed in ZINC15
LipidsFatty Acyls [FA] -> Eicosanoids [FA03] -> Prostaglandins [FA0301]
Human DrugsBreast Feeding; Lactation; Milk, Human; Antihypertensive Agents; Cardiovascular Agents; Prostaglandins, Synthetic; Vasodilator Agents
Physical DescriptionSolid
Collision Cross Section · 3 Einträge

198.6 Ų [M+H]+ [CCS Type: DT; Method: single field calibrated with Agilent tune mix (Agilent)]

201.3 Ų [M+H]+ [CCS Type: DT; Method: stepped-field]

199.8 Ų [M+H]+

Physikochemische Eigenschaften

Siedepunkt
530.2 · 530.2±50.0 °C(Predicted)
Dichte
1.221 · 1.221
pka
4.7 · 4.70±0.10(Predicted)

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

Toxikologische Informationen

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 3 Einträge

B01AC09

B - Blood and blood forming organs

QB - Blood and blood forming organs

Pharmacodynamics · 1 Eintrag

Epoprostenol has two major pharmacological actions: (1) direct vasodilation of pulmonary and systemic arterial vascular beds, and (2) inhibition of platelet aggregation. In animals, the vasodilatory effects reduce right and left ventricular afterload and increase cardiac output and stroke volume. The effect of epoprostenol on heart rate in animals varies with dose. At low doses, there is vagally mediated brudycardia, but at higher doses, epoprostenol causes reflex tachycardia in response to direct vasodilation and hypotension. No major effects on cardiac conduction have been observed. Additional pharmacologic effects of epoprostenol in animals include bronchodilation, inhibition of gastric acid secretion, and decreased gastric emptying. No available chemical assay is sufficiently sensitive and specific to assess the in vivo human pharmacokinetics of epoprostenol.

Mechanism of Action · 1 Eintrag

Prostaglandins are present in most body tissues and fluids and mediate many biological functions. Epoprostenol (PGI2) is a member of the family of prostaglandins that is derived from arachidonic acid. The major pharmacological actions of epoprostenol is ultimately inhibition of platelet aggregation. Prostacycline (PGI2) from endothelial cells activate G protein-coupled receptors on platelets and endothelial cells. This activation causes adenylate cyclase to produce cyclic AMP which inhibits further platelet activation and activates protein kinase A. Cyclic AMP also prevents coagulation by preventing an increase in intracellular calcium from thromboxane A2 binding. PKA then continues the cascade by phosphorylating and inhibiting myosin light-chain kinase which leads to smooth muscle relaxation and vasodilation. Notably, PGI2 and TXA2 work as physiological antagonists.

Biological Half-LifeThe in vitro half-life of epoprostenol in human blood at 37°C and pH 7.4 is approximately 6 minutes; the in vivo half-life of epoprostenol in humans is therefore expected to be no greater than 6 minutes.
Metabolism/Metabolites · 1 Eintrag

Epoprostenol is metabolized to 2 primary metabolites: 6-keto-PGF1α (formed by spontaneous degradation) and 6,15-diketo-13,14-dihydro-PGF1α (enzymatically formed), both of which have pharmacological activity orders of magnitude less than epoprostenol in animal test systems. Fourteen additional minor metabolites have been isolated from urine, indicating that epoprostenol is extensively metabolized in humans.

FDA Pharmacological Classification · 6 Einträge

DCR9Z582X0

EPOPROSTENOL

Established Pharmacologic Class [EPC] - Prostacycline Vasodilator

Chemical Structure [CS] - Prostaglandins I

Physiologic Effects [PE] - Vasodilation

Epoprostenol is a Prostacycline Vasodilator. The physiologic effect of epoprostenol is by means of Vasodilation.

MeSH Pharmacological Classification · 2 Einträge

Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS.

Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.

Absorption, Distribution and Excretion · 2 Einträge

Epoprostenol is metabolized to 2 primary metabolites: 6-keto-PGF1α (formed by spontaneous degradation) and 6,15-diketo-13,14-dihydro-PGF1α (enzymatically formed), both of which have pharmacological activity orders of magnitude less than epoprostenol in animal test systems. Fourteen additional minor metabolites have been isolated from urine, indicating that epoprostenol is extensively metabolized in humans.

357 mL/kg

Tissue LocationsAdipose Tissue
Cellular LocationsEndoplasmic reticulum
Metabolite PathwaysAcetaminophen Action Pathway

Anwendungen

VerwendenInhibitor (platelet). [Names previously used: Prostacyclin, PGI2, Prostagland in I2, Prostaglandin X, PGX].

Vor- und nachgelagerte Produkte

Vorgelagerte Rohstoffe

Kalium-tert-butanolat

Zugehörige Reaktionen

4
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 483261
HRID 483261als Edukt
Reaktionsgleichung von HRID 1708154
HRID 1708154als Edukt
Reaktionsgleichung von HRID 1881348
HRID 1881348als Edukt
Reaktionsgleichung von HRID 1908709
HRID 1908709als Edukt

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung